REPLACE: safety and efficacy of basiliximab in calcineurin inhibitor intolerant long-term kidney transplant recipients treated with mycophenolic acid and steroids
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Basiliximab (Primary)
- Indications Renal transplant rejection
- Focus Pharmacokinetics
- Acronyms REPLACE
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 31 Oct 2009 Actual end date (1 Dec 2008) and actual patient number (7) added as reported by ClinicalTrials.gov.
- 20 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.